NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, announces it is investigating potential securities claims on behalf of shareholders of Osiris Therapeutics, Inc. (NASDAQ: OSIR) resulting from allegations that Osiris Therapeutics may have issued materially misleading business information to the investing public.
On November 16, 2015, Osiris Therapeutics disclosed that it has determined to correct the revenue recognition for three contracts which will result in a decrease in product revenues of $1.8 million in the first quarter of 2015, a decrease in product revenue of $1.0 million in the second quarter, an increase in product revenues of $0.8 million in the third quarter of 2015 and a decrease in product revenues of $1.1 million in 2014. On this news, shares of Osiris Therapeutics fell sharply during intraday trading on November 17, 2015, damaging investors.
Rosen Law Firm is preparing a class action lawsuit to recover losses suffered by Osiris Therapeutics investors. If you purchased shares of Osiris Therapeutics on or before November 16, 2015, please visit the firm’s website at http://rosenlegal.com/cases-786.html for more information. You may also contact Phillip Kim, Esq. or Kevin Chan, Esq. of Rosen Law Firm toll free at 866-767-3653 or via email at email@example.com or firstname.lastname@example.org.
Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.
Attorney Advertising. Prior results do not guarantee a similar outcome.